Antheia Bio
About Antheia Bio
Antheia Bio is focused on delivering commercial-scale shipments of thebaine, a key starting material for Narcan. The company leverages synthetic biology to produce biosynthetic Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs) for essential medicines.
Business Information
Target Customers
Industry Categories
Business Model
Funding Timeline
Round | Date | Amount | Investors |
---|---|---|---|
Series C | Jun 04, 2025 | $56.0M | Unknown |
Founders
Christina Smolke
CEO and Co-Founder
Investors
No investor information available.
Recent Mentions
Congratulations to Christina Smolke and the @antheiabio team on closing a $56 million Series C round and delivering their first commercial-scale shipment of thebaine, a key starting material for Narcan! https://t.co/Sm5pLvAUyu https://t.co/sssOk7Egd9
Congratulations to Christina Smolke and the @antheiabio team on closing a $56 million Series C round and delivering their first commercial-scale shipment of thebaine, a key starting material for Narcan! #synbio https://t.co/8wEuzUMBxi
Similar Startups
Antheia
95% matchAntheia Inc. is a next-generation pharmaceutical ingredient manufacturer that utilizes synthetic bio...
Therini Bio
87% matchTherini Bio is a biotechnology company focused on developing innovative therapeutics for neurodegene...
Kiin Bio
87% matchKiin Bio is an AI-powered drug discovery platform that develops virtual scientists to accelerate the...
KiinBio
86% matchKiinBio is a British life sciences startup that has developed a Virtual Scientist Platform for drug ...